# NAD+: The Control Case, and Why It Is Not a Peptide > NAD+: The Control Case for Oral Availability — Research Peptide Fundamentals — NAD+ in the Research Peptide Fundamentals series: an endogenous coenzyme, not a peptide, whose oral precursors raise blood levels in controlled trials and show what real absorption looks like among research peptides. **03 / ABSORPTION** An endogenous coenzyme whose oral precursors demonstrably raise blood levels, and a clean demonstration that what makes a molecule orally available is size and chemistry rather than origin. ## The short version NAD+ is not a peptide. It is a coenzyme, a small molecule every living cell makes and uses constantly to move electrons around during energy production. It is on this site deliberately, as a control case. It is also the purest test of the word natural. Nothing is more endogenous than a molecule the body manufactures in every cell. And swallowed NAD+ itself is still poorly taken up intact, which is why the human trials almost all use precursors, meaning smaller building blocks the body converts into NAD+ once they are inside. Those precursors work by mouth in a way no peptide on this site does. Controlled trials show oral nicotinamide riboside and oral nicotinamide mononucleotide raising blood NAD+ dose-dependently [14][17]. That is what genuine oral bioavailability looks like when it is present. What has not followed is the clinical payoff. Raising the number in the blood has not translated into demonstrated outcomes, and a 2025 review says so directly [13]. ## What it is NAD+, nicotinamide adenine dinucleotide, is a dinucleotide: nicotinamide mononucleotide joined to adenosine monophosphate by two bridging phosphate groups, giving a pyridine nicotinamide ring and an adenine ring. The oxidised form is NAD+ and the reduced form is NADH. By size and chemistry it belongs to a different world from the two peptides on this site. It has no peptide bonds, so the proteases that dismantle a swallowed peptide have nothing to cut. Its oral problem is a different one, closer to a transport and stability question than to a digestion question. Its commercial forms matter for reading any claim about it. NAD+ and its precursors, chiefly nicotinamide riboside and nicotinamide mononucleotide, are sold as dietary supplements. Injectable and intravenous NAD+ is typically compounded rather than approved. It is not an approved drug, the regulatory status of nicotinamide mononucleotide as a supplement ingredient has been contested by the Food and Drug Administration on the grounds that it was investigated as a drug, and supplement-grade products vary widely in purity and actual content with no guarantee of third-party testing. ## How it works NAD+ has two jobs, and only the second one is consumed. As a redox carrier it shuttles electrons through glycolysis, the citric acid cycle and oxidative phosphorylation, which is how cells turn food into ATP. In that role it cycles between NAD+ and NADH endlessly and is not used up. As a substrate it is destroyed. Signalling enzymes cleave NAD+ to do their work: the sirtuins, a family of NAD-dependent deacylases involved in gene regulation, the PARPs, chiefly PARP1, which respond to DNA damage, and the ectoenzymes CD38 and CD157, which are involved in inflammation. Those enzymes compete for a shared pool [16]. Tissue NAD+ falls with age, in part because CD38 activity rises, and that observation is the entire rationale for supplementing with precursors [16]. The logic is straightforward: if the pool is being drained faster, refill it upstream. Whether refilling it produces a health outcome is a separate question, and it is the one that remains open. ## What the research shows On the narrow question of whether an oral precursor raises the blood level, the answer is yes and it is dose-dependent. Nicotinamide riboside given at 100 to 1000 mg per day for 8 weeks raised whole-blood NAD+ by 22 percent, 51 percent and 142 percent at the three dose levels in healthy overweight adults, with no flushing and no significant difference in adverse events from placebo at any dose [17]. A multicentre double-blind randomised trial of oral nicotinamide mononucleotide at 300 to 900 mg per day for 60 days in middle-aged adults likewise raised blood NAD+ dose-dependently, and reported improved walking distance and quality-of-life scores against placebo. The investigators identified 600 mg per day as the optimal dose among those tested and reported no safety issues at any dose [14]. A smaller study took the question further into physiology. Ten weeks of oral nicotinamide mononucleotide at 250 mg per day improved muscle insulin sensitivity and remodelled insulin signalling in prediabetic postmenopausal women [15]. The doses named above are the doses used in those trials. They are reported here as study design, not as guidance for anyone. Set against that, the summary of the field is markedly more cautious. A 2025 narrative review of the human clinical evidence on NAD+ precursor supplementation in ageing concluded that human trials have shown limited efficacy, that age-related NAD+ decline has been consistently observed in only a limited number of human studies, and that data on tissue-specific NAD+ dynamics remain sparse, with more clinical study of systemic and tissue-specific NAD+ metabolism needed rather than reliance on extrapolation from rodents [13]. ## Cautions, disputes and what is not settled This page carries no community-report summary and no citation-backed safety list, because the corpus behind this site records neither for NAD+. What it does record is a set of disputes, and they are worth stating without dressing them up. - Oral NAD+ itself is poorly taken up by cells intact. Most commentators treat precursors as the rational oral approach, and some argue that plain oral NAD+ capsules are largely ineffective. - Raising blood NAD+ is well demonstrated. Translating that into hard clinical outcomes such as longevity or disease prevention in humans is not, and the 2025 review reached exactly that conclusion [13]. - Much of the strongest anti-ageing data comes from rodents and may not extrapolate to people. - Intravenous NAD+ wellness therapy is marketed aggressively and rests on minimal controlled evidence. Infused NAD+ is cleared from plasma rapidly, and infusions run too fast can cause chest or abdominal discomfort, flushing and nausea. - Compounded injectable NAD+ carries a contamination risk. The Food and Drug Administration issued a Class I recall of a compounded NAD+ injection for elevated bacterial endotoxin. - A theoretical concern exists that boosting NAD+ could support the metabolism of an existing cancer, since proliferating cells depend on it. NAD+ has dual, context-dependent roles in oncology, and caution is advised in cancer populations. - Supplement-grade product quality varies widely, and third-party testing is not guaranteed. NAD+ and its precursors are not prohibited by the World Anti-Doping Agency. None of the above is medical advice, and nothing here recommends a product or a dose. ## Where it fits in the oral question NAD+ earns its place on this site by being the counter-example that keeps the argument honest. If the claim were that nothing works by mouth, NAD+ precursors would falsify it immediately. Oral nicotinamide riboside and oral nicotinamide mononucleotide raise a measured blood marker, dose-dependently, in controlled trials [14][17]. That is unambiguous oral bioavailability. But look at what is doing the work. These are small nucleotide-derived molecules with no peptide bonds, absorbed by ordinary small-molecule routes and converted downstream by enzymes the body already runs. Nothing about that success is transferable to a fifteen-amino-acid peptide in a capsule. It is a different chemistry solving a different problem. And there is a second lesson, which is the difference between a marker and an outcome. Blood NAD+ went up. Whether anything that matters went up with it remains, on the published human evidence, unresolved [13]. A route that demonstrably delivers a molecule is a necessary step, not a finished argument. The oral peptide field has not yet cleared the first step for most of its compounds, and the NAD+ literature is a useful reminder that clearing it is not the same as arriving. --- An independent reading desk on what survives the trip from mouth to bloodstream, selling nothing, prescribing nothing and endorsing no capsule, spray or protocol.